For men with early stage, low-risk prostate cancer, treatment with hypofractionated radiation therapy (RT) offers comparable health-related quality of life outcomes in one-third less treatment time than conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Survival rates for elderly patients who received stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) rose from roughly 40 to 60 percent over the past decade, concurrent with the increasing adoption of SBRT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely-hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Enhanced, culturally-competent communication with early stage lung cancer patients can narrow racial gaps in curative treatment completion and increase treatment rates for all races, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Although approximately 50 percent of cancer patients in developing countries need radiation therapy (RT) to treat their disease, up to half of these patients do not have access to it, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
High dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity and excellent cancer control rates, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
In the largest trial conducted for average risk (A-R) medulloblastoma, survival rates following reduced radiation therapy (RT) boost volumes were comparable to standard treatment volumes for the primary tumor site but lower doses of craniospinal axis irradiation were associated with higher event rates and worse survival, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBRT), according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
A new analysis of records in the Veteran’s Affairs Central Cancer Registry demonstrates a clear positive impact of the increased use of stereotactic body radiation therapy (SBRT) to treat patients with stage I non-small cell lung cancer (NSCLC) in recent years, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
For patients with stage II and III non-small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation (CRT), hypofractionated radiation therapy (RT) results in similar overall survival (OS) and progression-free survival (PFS) rates, limited severe side effects and shorter treatment times when compared to conventional RT, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Three leading national cancer organizations today issued a joint clinical practice guideline update for physicians treating women with breast cancer who have undergone a mastectomy.
In light of the findings from the Prostate Testing for Cancer and Treatment (ProtecT) trial published today in the New England Journal of Medicine, the American Society for Radiation Oncology (ASTRO) would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study.
The American Society for Radiation Oncology (ASTRO) announced today the press program for its 58th Annual Meeting, which includes multiple reports from phase III clinical trials, researchers from leading institutions in the U.S. and abroad, and examinations of a range of cancer types and patient populations.
The American Society for Radiation Oncology (ASTRO) has selected 44 cancer researchers and clinicians to receive a total of $36,500 in individual awards for studies being presented at the Society’s annual scientific meeting.
The American Society for Radiation Oncology (ASTRO) has selected four early career scientists to receive a total of $275,000 in research awards, including one winner of the ASTRO Junior Faculty Career Research Training Award and three recipients of ASTRO Resident/Fellows in Radiation Oncology Research Seed Grants.
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical practice statement, “Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An ASTRO Clinical Practice Statement Using the RAND/UCLA Appropriateness Method.”
The American Society for Radiation Oncology (ASTRO) has chosen Theresa A. Keresztes, a resident of Wellesley, Massachusetts, to receive the 2016 Survivor Circle Award.
Members of the American Society for Radiation Oncology (ASTRO) have elected five new officers to the Society’s Board of Directors, including President-elect, Secretary-Treasurer-elect, and Vice-chairs of three of ASTRO’s five councils (Clinical Affairs and Quality, Education and Government Relations).
The Chair of the American Society for Radiation Oncology (ASTRO), Bruce D. Minsky, MD, FASTRO, issued the following statement supporting witness testimony from today’s Senate Finance Committee hearing, “Examining the Stark Law: Current Issues and Opportunities,” during which all three witnesses testified in agreement that changes are needed to the law’s in-office ancillary services (IOAS) exception.
Ten distinguished members of the American Society for Radiation Oncology (ASTRO) have been named ASTRO Fellows, in the 10th anniversary year that the designation has been awarded.
The American Society for Radiation Oncology (ASTRO) has selected Haakon Ragde, MD, as its 2016 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics.
Three leaders in radiation oncology, including clinicians and researchers from Duke University, Massachusetts General Hospital and Cedars-Sinai Medical Center, have been named recipients of the American Society for Radiation Oncology (ASTRO) Gold Medal, the highest honor bestowed upon members of the world’s largest radiation oncology society.
Researchers with novel ideas for high-risk, high-reward projects are encouraged to apply for the Radiation Oncology Institute’s (ROI) Innovative Projects in Radiation Oncology program, which will award grants of up to $50,000 to multiple projects that address the highest impact research questions for the field.
Radiation oncologists from across the United States convened on Capitol Hill yesterday to encourage members of Congress to invest in cancer research with sustainable and predictable funding and to protect patients’ access to high quality cancer care through value-based physician payment models.
Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 58th Annual Meeting, which will feature a record number of abstracts on radiation oncology clinical trials and research and keynote addresses from former U.S. Secretary of Health and Human Services Kathleen Sebelius, the current CEO of the Massachusetts General Physicians Organization and a top safety executive from Delta Air Lines.
The American Society for Radiation Oncology (ASTRO) has selected The Samfund, a Boston-based cancer organization, to receive one of two ASTRO 2016 Survivor Circle Grants.
The American Society for Radiation Oncology (ASTRO) has selected a Boston-based organization, Boston Cancer Support, to receive one of two 2016 ASTRO Survivor Circle grants.
The American Society for Radiation Oncology (ASTRO) and radiation oncologists nationwide hailed today’s introduction on Capitol Hill of federal legislation that would drive alternative payment models, protect patients and reduce Medicare costs by closing a costly loophole in the physician self-referral law.
The Radiation Oncology Institute (ROI) encourages researchers to apply for competitive grants totaling $200,000 over two years for projects that leverage the unique opportunities afforded by advances in “big data” analytics in radiation oncology.
The International Journal of Radiation Oncology • Biology • Physics’ (Red Journal) May edition is a special issue focused entirely on particle therapy. It will feature papers showcasing the “best available evidence” on the value of particle therapy, as well as editorials and commentaries about its place in the radiation therapy (RT) arsenal.
Wide variability exists in radiation treatment decisions following neoadjuvant chemotherapy (NAC) and surgery for breast cancer, according to a review of the American College of Surgeons Oncology Group (ACOSOG) Z1071, a prospective trial. ACOSOG is now part of the Alliance for Clinical Trials in Oncology.
A prospective study examining a trimodality treatment approach in localized bladder cancer cases using adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT) found that the bladder preservation rate at three years was 83 percent.
Increased travel distance to a cancer treatment facility negatively impacts the likelihood that patients with stage II/III rectal cancer will receive radiation therapy (RT) to treat their disease, according to a study analyzing 26,845 patient records from the National Cancer Data Base (NCDB) that was published in the March 2016 issue of International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
In light of conflicting and inconclusive clinical data on the benefit of radiation therapy in cancer patients with the BRCA1 and BRCA2 mutation, a clinical review examined the current status of data regarding BRCA1 and BRCA2 deficiency and radiation therapy sensitivity and a potential strategy to intensify the effects of radiation therapy (RT) by poly(ADP-ribose) polymerase inhibitors (PARPi), the pharmacologic drugs under investigation as monotherapy for the treatment of breast cancer in patients with BRCA1 and BRCA2 mutations.
Throat cancer patients exposed to both human papillomavirus (HPV) and tobacco smoke demonstrate a pattern of mutations along several key cancer genes, according to research presented today at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
The addition of chemotherapy (CT) to radiation therapy (RT) improves survival rates among a subset of elderly head and neck cancer patients, specifically those ages 71 to 79 with low comorbidity scores and advanced disease stage, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
The majority of patients with locally advanced head and neck cancers (LAHNC) rely on cost-coping strategies that alter their lifestyle in order to manage the financial burden of their care, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
Compared to patients with non-Medicaid insurance, uninsured patients and patients with Medicaid are more likely to present with advanced stages of head and neck cancer and have higher overall and cancer-specific mortality rates, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
Head and neck cancer patients who receive induction chemotherapy (IC; chemotherapy administered prior to radiation therapy) rather than the standard treatment of concurrent chemoradiation (CRT) do not benefit from increased survival rates and are less likely to receive a full course of radiation, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
The 2016 Multidisciplinary Head and Neck Cancer Symposium, sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS), will explore the heterogeneous group of tumors in head and neck cancers and the various complexities and factors in providing treatment.
The American Society for Radiation Oncology (ASTRO) commends the proposed investment in cancer-related research announced in the Fiscal Year 2017 Budget released yesterday by the White House.
Advances in Radiation Oncology, ASTRO’s new original research journal, has closed its first issue with research including a phase II clinical trial in prostate cancer, a prospective trial in quality of life for breast cancer patients receiving radiotherapy and several clinical and medical physics reports on the use of stereotactic body radiotherapy.
A phase 1 trial examining precision hypofractionated radiation therapy (RT) in locally advanced non-small cell lung cancer (NSCLC) cases found that higher RT doses in a shorter time span were potentially cost-effective and generally well tolerated, while allowing for fewer radiation treatments.
The 2016 Multidisciplinary Head and Neck Cancer Symposium, sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO) and the American Head & Neck Society (AHNS), will explore the heterogeneous group of tumors in head and neck cancers and the various complexities and factors in providing treatment.
The American Society for Radiation Oncology (ASTRO) applauds President Obama and Vice President Biden for affirming their commitment to improving cancer patients’ lives through the “moonshot” effort in cancer research announced in the President’s State of the Union speech on Tuesday.
December 18, 2015 – The American Society for Radiation Oncology (ASTRO) applauds Congress for today’s passage of S. 2425 to freeze radiation oncology freestanding center payment rates for 2017-2018 at the levels set under the Medicare Physician Fee Schedule for 2016.
A new template published by the American Society for Radiation Oncology (ASTRO) standardizes and streamlines the creation of patient-focused plans for long-term cancer survivor care following radiation therapy (RT).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right